TORONTO, Aug. 25 /CNW/ - Lorus Therapeutics Inc. (“Lorus”), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that further to its previously announced transaction with High Tech Beteiligungen GmbH & Co. KG to issue 28.8 million common shares at $0.36 per share for gross proceeds of $10.4 million, it has successfully filed its final prospectus qualifying the distribution of such shares. The offering is scheduled to close by the end of August 2006.
